Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PFKFB3 antisense RNA 1 (PFKFB3-AS1)
- Target
- PFKFB3-AS1
- Molecular classification
- Long non-coding RNA, Antisense RNA, Regulatory RNA
01
Overview
PFKFB3 antisense RNA 1 (PFKFB3-AS1) is a long non-coding RNA located antisense to the PFKFB3 gene. It is overexpressed in cancers such as gastric cancer and correlates with advanced tumor stage and poor prognosis. PFKFB3-AS1 regulates cellular metabolism and proliferation through enhancement of PFKFB3 mRNA and protein expression—PFKFB3 encodes an essential enzyme in the glycolytic pathway that facilitates the Warburg effect in cancer cells. Knockdown of PFKFB3-AS1 reduces PFKFB3 expression, glycolytic flux, and cell proliferation, while its overexpression has the reverse effect. PFKFB3-AS1 is not currently considered a direct therapeutic target, but may serve as a biomarker for cancer progression and prognosis.
- Other names
- PFKFB3-AS1
02
Mechanism of action
Not applicable for drugs targeting PFKFB3-AS1, as none are reported. PFKFB3-AS1 acts by modulating PFKFB3 expression at the RNA level, thereby influencing glycolytic activity and cancer cell proliferation.
03
Biological functions
Regulation of gene expression (specifically of PFKFB3)Regulation of cell proliferationRegulation of glycolysisPossible roles in cell cycle progression (through its regulation of glycolytic metabolism and cellular proliferation)
04
Disease associations
Cancer (overexpressed in several cancers, especially gastric cancer, and correlates with poor prognosis)Potential involvement in other malignancies (e.g., possible relevance in metabolic remodeling in cancer)
05
Safety considerations
Not established for direct therapeutic targeting, as PFKFB3-AS1 itself is not a drug target at this time. Safety challenges for lncRNA-targeted drugs in general can include specificity and off-target effects.
06
Biomarkers
PFKFB3-AS1 expression level (may serve as a biomarker for poor prognosis in gastric cancer)Co-expression with PFKFB3 (high expression correlates with advanced tumor stage and adverse outcomes)
Beyond the preview
Go deeper on PFKFB3 antisense RNA 1 (PFKFB3-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PFKFB3 antisense RNA 1 (PFKFB3-AS1).